Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.57 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.57 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10500161 | 0.89 | DPP8 (0.58) | DPP8DPP9TGM2MGLLRAB9A | |
| SCHEMBL6418689 | 0.88 | DPP8 (0.58) | DPP8DPP9TGM2MGLLRAB9A | |
| SCHEMBL11391394 | 0.86 | DPP8 (0.57) | DPP8DPP9TGM2MGLLRAB9A | |
| SCHEMBL10825541 | 0.86 | DPP8 (0.57) | DPP8DPP9TGM2MGLLRAB9A | |
| SCHEMBL13647947 | 0.86 | MGLL (0.67) | DPP8DPP9TGM2MGLLRAB9A | |
| SCHEMBL6397257 | 0.86 | DPP8 (0.57) | DPP8DPP9TGM2MGLLRAB9A | |
| SCHEMBL10756101 | 0.85 | DPP8 (0.59) | DPP8DPP9TGM2MGLLRAB9A | |
| SCHEMBL6942547 | 0.85 | HTT (0.68) | DPP8DPP9TGM2MGLLRAB9A | |
| SCHEMBL11099186 | 0.85 | DPP8 (0.56) | DPP8DPP9TGM2MGLLRAB9A | |
| SCHEMBL147036 | 0.85 | DPP8 (0.59) | DPP8DPP9TGM2MGLLRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825187-B2 | CARBAPENEM DERIVATIVES SUBSTITUTED AT THE 2-POSITION WITH A SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP; USE AGAINST ANTIBIOTIC RESISTANT STAPHYLOCOCCUS AUREUS AND PSEUDOMONAS AERUGINOSA, ENTEROCOCCI AND INFLUENZA VIRUS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| EP-1251133-B1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA (JP) | 2004-10-13 | — | — | EP | disclosed |
| US-6680313-B2 | 1-HYDROXYETHYL-2(IMIDAZO(5,1B)THIAZOL-2-YL-1-CARBAPEN-2-EM-3-C CARBOXYLIC ACID OR SALT, EXCELLENT ANTIBIOTIC ACTIVITY AGAINST A WIDE SPECTRUM OF BACTERIA | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-01-20 | — | — | US | disclosed |
| US-20030027809-A1 | Novel carbapenum derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-02-06 | — | — | US | disclosed |
| US-20030022881-A1 | Novel carbapenem derivatives of quarternary salt type | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
| EP-1251134-A1 | NOVEL CARBAPENEM DERIVATIVES OF QUATERNARY SALT TYPE | MEIJI SEIKA KAISHA LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
| EP-1251133-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027809-A1 | Novel carbapenum derivatives | DHPS, DPEP1, OXA1L | DPP8 64/4885DPP9 206/4885TGM2 3877/4885 |
| US-20030022881-A1 | Novel carbapenem derivatives of quarternary salt type | DHPS, HDHD5, RRP15 | DPP8 173/4885DPP9 312/4885TGM2 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.